Article and Video CATEGORIES

Cancer Journey

Search By

ABOUT
Denise Brock

Denise has over 30 years of varying experience in the healthcare arena.  In August 2009 she joined The Global Resource for Advancing Cancer Education as one of its first employees.  She has grown with the organization and now oversees the operational movement of programs, efficiency, and effectiveness within the organization, as well as the daily processes and functions.  

 

Join us for the 2024 Blood Cancers OncTalk!
dbrock
This free, live event will be held online on Saturday, October 12, 2024 at 8:00 AM Pacific! Register below!
Author
Denise Brock
Image
Blood Cancers OncTalk

Registration is now open!


Join us for the annual 2024 Blood Cancers OncTalk! 

Register Now!

This live, virtual, interactive patient education event includes presentations and panel discussions covering general subjects relevant to a diverse range of blood cancers and treatment options, as well as an opportunity to speak with the experts in a Q&A session.  

Speakers includes top medical professionals presenting  patient-focused discussions to educate the patient and caregiver communities to become advocates for their own health and well-being. 


The full agenda and faculty bio's will be available soon! 
Video Language

Next Previous link

Previous PostNext Post

Related Content

Online Community

A Brief Tornado.  I love the analogy Dr. Antonoff gave us to describe her presentation.  I felt it earlier too and am looking forward to going back for deeper dive.

Dr. Singhi's reprise on appropriate treatment, "Right patient, right time, right team".

While Dr. Ryckman described radiation oncology as "the perfect blend of nerd skills and empathy".  

I hope any...

My understanding of ADCs is very basic. I plan to study Dr. Rous’ discussion to broaden that understanding.

Here's the webinar on YouTube.  It begins with the agenda. Note the link is a playlist, which will be populated with shorts from the webinar on specific topics

An antibody–drug conjugate (ADC) works a bit like a Trojan horse. It has three main components:

  1. The antibody, which serves as the “horse,” specifically targets a protein found on cancer...

Bispecifics, or bispecific antibodies, are advanced immunotherapy drugs engineered to have two binding sites, allowing them to latch onto two different targets simultaneously, like a cancer cell and a T-cell, effectively...

Recent Comments

JOIN THE CONVERSATION
Webinar OnDemand
By JanineT GRACE … on
My understanding of ADCs is…
By JanineT GRACE … on
Right patient, right time,…
By JanineT GRACE … on
A Brief Tornado.  I love the…
By JanineT GRACE … on